Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837692 | 0.86 | MEN1 (0.75) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL837706 | 0.85 | MEN1 (0.74) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4817753 | 0.82 | KDM4E (0.70) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL30917200 | 0.82 | KMT2A (0.70) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL838429 | 0.82 | KMT2A (0.70) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL14420787 | 0.79 | MEN1 (0.65) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL1702071 | 0.79 | MEN1 (0.72) | RAB9AMAPTMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL13518268 | 0.78 | MEN1 (0.70) | RAB9AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL1061819 | 0.77 | LMNA (0.65) | RAB9AMAPTKMT2AKDM4ELMNA | |
| SCHEMBL3110763 | 0.75 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | disclosed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | disclosed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | disclosed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | disclosed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | RAB9A 687/4885MAPT 3636/4885MEN1 3957/4885 |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | RAB9A 789/4885MAPT 3980/4885MEN1 4212/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | RAB9A 400/4885MAPT 4358/4885MEN1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.